Financial Analysis

11. EMPLOYEE BENEFIT PLANS Retirement Plan We have a 401(k) savings plan covering substantially all of our employees in the United States, as well as other defined contribution plans covering certain non-U.S. employees. During 2025, 2024, and 2023, we made matching contributions of $48 million, $45 million, and $46 million, respectively, related to our defined contribution plans. Deferred Compensation Plan The Illumina, Inc. Deferred Compensation Plan (the Plan) allows senior level employees to contribute up to 60% of their base salary and 100% of their variable cash compensation, and members of the board of directors to contribute up to 100% of their director fees and equity awards. Under the Plan, we credit the participants contributions with earnings that reflect the performance of certain independent investment funds. On a discretionary basis, we may also make employer contributions to participant accounts in any amount determined by us. The vesting schedules of employer contributions are at the sole discretion of the Compensation Committee. However, all employer contributions shall become 100% vested upon the occurrence of the participants disability, death or retirement or a change in control of Illumina. The benefits under this plan are unsecured. Participants are generally eligible to receive payment of their vested benefit at the end of their elected deferral period or after termination of their employment for any reason or at a later date to comply with the restrict …

CompensationAndEmployeeBenefitPlansTextBlock · excerpt; the full note is in the filing

5. DEBT AND OTHER COMMITMENTS Summary of Term Debt Obligations In millions December 28, 2025 December 29, 2024 Principal amount of 2025 Term Notes outstanding 500 Principal amount of 2026 Term Notes outstanding 500 500 Principal amount of 2027 Term Notes outstanding 500 500 Principal amount of 2030 Term Notes outstanding 500 Principal amount of 2031 Term Notes outstanding 500 500 Unamortized discounts and debt issuance costs (11) (11) Net carrying amount of term debt 1,989 1,989 Less: current portion 499 499 Term debt, non-current $ 1,490 $ 1,490 Fair value of term debt outstanding (Level 2) $ 1,977 $ 1,940 Interest expense recognized on our outstanding debt obligations, which included amortization of debt discounts and debt issuance costs, was $99 million in 2025 and 2024, respectively, and $74 million in 2023. 4.750% Term Notes due 2030 (2030 Term Notes) On November 25, 2025, we issued $500 million aggregate principal amount of 2030 Term Notes. After deducting discounts and issuance costs, we received net proceeds of $495 million. The 2030 Notes, which mature on December 12, 2030, accrue interest at a rate of 4.750% per annum, payable semi-annually on June 12 and December 12 of each year, beginning on June 12, 2026. We may redeem for cash all or any portion of the 2030 Term Notes, at our option, at any time prior to maturity at make-whole premium redemption prices as defined in the form of the notes. 4.650% Term Notes due 2026 (2026 Term Notes) On September 9, 2024, we issu …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Our revenue is generated from the sale of products and services. Product revenue consists of sales of instruments and consumables used in genetic analysis. Service and other revenue consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and prior to the Spin-Off of GRAIL on June 24, 2024, cancer detection testing services related to the GRAIL business. Revenue by Source 2025 2024 2023 In millions Sequencing Microarray Total Sequencing Microarray Total Sequencing Microarray Total Consumables $ 2,939 $ 288 $ 3,227 $ 2,858 $ 297 $ 3,155 $ 2,790 $ 293 $ 3,083 Instruments 465 17 482 484 17 501 685 19 704 Total product revenue 3,404 305 3,709 3,342 314 3,656 3,475 312 3,787 Service and other revenue 581 53 634 651 65 716 637 80 717 Total revenue $ 3,985 $ 358 $ 4,343 $ 3,993 $ 379 $ 4,372 $ 4,112 $ 392 $ 4,504 Revenue by Geographic Area Based on region of destination (in millions) 2025 2024 2023 Americas (1) $ 2,406 $ 2,441 $ 2,521 Europe 1,264 1,185 1,140 Greater China (2) 243 308 384 Asia-Pacific, Middle East and Africa (3) 430 438 459 Total revenue $ 4,343 $ 4,372 $ 4,504 _____________ (1) Americas revenue included United States revenue of $2,243 million, $2,288 million, and $2,359 million in 2025, 2024, and 2023, respectively. (2) Region includes revenue from China, Taiwan, and Hong Kong. (3) Region includes revenue from Russia and Turkey.

DisaggregationOfRevenueTableTextBlock

3. INVESTMENTS AND FAIR VALUE MEASUREMENTS Strategic Investments Marketable Equity Securities Our short-term investments consist of marketable equity securities, primarily our retained investment in GRAIL subsequent to the Spin-Off. As of December 28, 2025 and December 29, 2024, the fair value of our marketable equity securities totaled $215 million and $93 million, respectively. Gains (losses) recognized in other income (expense), net on marketable equity securities were as follows: In millions 2025 2024 (1) 2023 Net gains (losses) recognized during the period $ 315 $ (310) $ (2) Less: Net gains (losses) recognized during the period on securities disposed of during the period 150 (2) Net unrealized gains (losses) recognized during the period on securities still held at the reporting date $ 165 $ (310) $ _____________ (1) Subsequent to the Spin-Off of GRAIL, we recognized a loss of $309 million in 2024 on our retained investment. Non-Marketable Equity Securities As of December 28, 2025 and December 29, 2024, non-marketable equity securities, without readily determinable fair values, included in other assets, were $58 million and $26 million, respectively. Venture Funds We invest in three venture capital investment funds (the Funds), which are accounted for as equity-method investments. The aggregate carrying amount of the Funds, included in other assets, was $235 million and $201 million as of December 28, 2025 and December 29, 2024, respectively. We recorded net gains of $22 …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

10. INCOME TAXES Income (loss) before income taxes summarized by region was as follows: In millions 2025 2024 2023 United States $ 331 $ (1,834) $ (1,735) Foreign 755 655 618 Total income (loss) before income taxes $ 1,086 $ (1,179) $ (1,117) The provision for income taxes consisted of the following: In millions 2025 2024 2023 Current: Federal $ $ 6 $ (5) State 13 18 6 Foreign 104 137 77 Total current provision 117 161 78 Deferred: Federal 106 (59) (13) State 19 (56) (26) Foreign (6) (2) 5 Total deferred benefit 119 (117) (34) Total tax provision $ 236 $ 44 $ 44 During the year ended December 28, 2025, we adopted ASU 2023-09 to enhance the income tax disclosures regarding income taxes paid and the rate reconciliation disclosure. The provision for income taxes reconciles to the amount computed by applying the federal statutory rate to income (loss) before income taxes as follows: 2025 2024 2023 Dollars in millions $ % $ % $ % US federal statutory tax rate $ 228 21.0 % $ (248) 21.0 % $ (235) 21.0 % State and local income taxes, net of federal income tax effect (1) 22 2.0 % (36) 3.1 % (32) 2.9 % Foreign tax effects Singapore Statutory rate difference between Singapore and US (54) (5.0) % (110) 9.3 % (103) 9.2 % Change in valuation allowance (74) (6.8) % (3) 0.3 % 31 (2.8) % Nondeductible R&D expense 2 0.2 % 15 (1.3) % 2 (0.2) % Other 10 0.9 % 12 (1.0) % 3 (0.2) % United Kingdom Pillar 2 (Global Minimum Tax) top-up tax 10 0.9 % 54 (4.6) % % Other 15 1.4 % 4 (0.3) % (2) 0.2 % …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

9. LEGAL PROCEEDINGS We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. Shareholder Derivative Complaints On October 17, 2023, a stockholder derivative and class action complaint captioned Icahn Partners LP, et al. v. deSouza, et al. , purportedly brought on behalf of Illumina and public holders of Illuminas common …

LegalMattersAndContingenciesTextBlock · excerpt; the full note is in the filing

Accounting Pronouncements Adopted in 2025 In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures . The new standard includes enhanced income tax disclosures, specifically related to the rate reconciliation and income taxes paid for annual periods. The standard was effective for us beginning in fiscal year 2025. We adopted the standard on its effective date in fiscal year 2025 and applied the amendments retrospectively, as permitted, to all prior periods presented in the consolidated financial statements. See note 10. Income Taxes for additional details. Accounting Pronouncements Adopted in 2024 In December 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures . The new standard requires a company to disclose incremental segment information on an annual and interim basis, including significant segment expenses and measures of profit or loss that are regularly provided to the CODM. The standard does not change how an entity identifies its operating segments. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted the standard on its effective date in fiscal year 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. See note 12. Segment and Geographic Information for additional details. Accounting Pronouncements Pending Adoption In November 2024, the FASB is …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

2. REVENUE Our revenue is generated from the sale of products and services. Product revenue consists of sales of instruments and consumables used in genetic analysis. Service and other revenue consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and prior to the Spin-Off of GRAIL on June 24, 2024, cancer detection testing services related to the GRAIL business. Revenue by Source 2025 2024 2023 In millions Sequencing Microarray Total Sequencing Microarray Total Sequencing Microarray Total Consumables $ 2,939 $ 288 $ 3,227 $ 2,858 $ 297 $ 3,155 $ 2,790 $ 293 $ 3,083 Instruments 465 17 482 484 17 501 685 19 704 Total product revenue 3,404 305 3,709 3,342 314 3,656 3,475 312 3,787 Service and other revenue 581 53 634 651 65 716 637 80 717 Total revenue $ 3,985 $ 358 $ 4,343 $ 3,993 $ 379 $ 4,372 $ 4,112 $ 392 $ 4,504 Revenue by Geographic Area Based on region of destination (in millions) 2025 2024 2023 Americas (1) $ 2,406 $ 2,441 $ 2,521 Europe 1,264 1,185 1,140 Greater China (2) 243 308 384 Asia-Pacific, Middle East and Africa (3) 430 438 459 Total revenue $ 4,343 $ 4,372 $ 4,504 _____________ (1) Americas revenue included United States revenue of $2,243 million, $2,288 million, and $2,359 million in 2025, 2024, and 2023, respectively. (2) Region includes revenue from China, Taiwan, and Hong Kong. (3) Region includes revenue from Russia and Turkey. Contract Assets and Liabilities Contract asse …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

12. SEGMENT AND GEOGRAPHIC INFORMATION Reportable Segment Information As of December 28, 2025, we have one reportable segment, Core Illumina. Prior to the Spin-Off of GRAIL, on June 24, 2024, our reportable segments included both Core Illumina and GRAIL. See note 8 . GRAIL Spin-Off for details. We continue to disclose certain historical information for GRAIL prior to the Spin-Off. Segment information is consistent with how our Chief Operating Decision Maker (CODM), who is our Chief Executive Officer, reviews financial information, makes operating decisions, allocates resources, and assesses performance. We also consider the way budgets and forecasts are prepared and reviewed and the basis on which executive compensation is determined. Core Illumina: Core Illuminas products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina sells products and provides services to GRAIL, and vice versa, in accordance with contractual agreements between the entities. GRAIL: GRAIL is a healthcare company focused on early detection of multiple cancers. Prior to the Spin-Off of GRAIL into a separate, independent public company, GRAIL was required to be held and operated separately and independently from Illumina pursuant to the transitional measures ordered by the European Commission. Our CODM allocates resources and evaluates business performance based on revenues and net income (loss). Net income (lo …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

13. SUBSEQUENT EVENTS On January 30, 2026, we acquired SomaLogic and other specified assets from Standard BioTools for a $350 million upfront cash payment, subject to customary adjustments. The Stock Purchase Agreement, which we entered into on June 22, 2025, further provides for, in connection with the revenues generated from certain products and services, (i) royalty streams and (ii) up to $75 million in potential milestone payments to Standard BioTools. We also acquired an intellectual property portfolio on January 30, 2026 for a $50 million upfront cash payment.

SubsequentEventsTextBlock

2. ACQUISITIONS, INTANGIBLE ASSETS AND GOODWILL SomaLogic Acquisition On January 30, 2026, we acquired SomaLogic, a proteomics company that provides high-throughput protein measurement technology and related data analysis services, and other specified assets from Standard BioTools. We expect the acquisition to enhance our presence in the proteomics market and advance our multiomics strategy. The total purchase price consisted of the following: In millions Cash $ 382 Fair value of contingent consideration 81 Settlement of preexisting relationship (3) Total purchase price $ 460 Standard BioTools is eligible to receive up to $75 million in milestone payments, comprised of up to $25 million based on 2025 performance and up to $50 million based on 2026 performance, due upon the achievement of specified targets for net revenue generated from SOMAmer-based assay services and related products (the Milestone Contingent Consideration). In Q2 2026, we paid $25 million for the milestone payment earned for the 2025 performance period. In addition, Standard BioTools is entitled to receive a 2% royalty on net revenues generated from sales of SOMAmer-based next-generation sequencing (NGS) library preparation kits, paid quarterly for 10 years from the acquisition date and continuing through January 2036 (the Royalty Contingent Consideration). The aggregate acquisition date fair value of these contingent consideration arrangements was $81 million. We used a Monte Carlo simulation to estimate t …

BusinessCombinationDisclosureTextBlock · excerpt; the full note is in the filing

5. DEBT Summary of Term Debt Obligations In millions June 28, 2026 December 28, 2025 Principal amount of 2026 Term Notes outstanding $ 500 $ 500 Principal amount of 2027 Term Notes outstanding 500 500 Principal amount of 2030 Term Notes outstanding 500 500 Principal amount of 2031 Term Notes outstanding 500 500 Unamortized discounts and debt issuance costs (9) (11) Net carrying amount of term debt 1,991 1,989 Less: current portion 500 499 Term debt, non-current $ 1,491 $ 1,490 Fair value of term debt outstanding (Level 2) $ 1,959 $ 1,977 Interest expense, which included amortization of debt discounts and issuance costs, was $23 million and $46 million in Q2 2026 and YTD 2026, respectively, and $24 million and $49 million in Q2 2025 and YTD 2025, respectively. 4.750% Term Notes due 2030 (2030 Term Notes) In November 2025, we issued $500 million aggregate principal amount of 2030 Term Notes, which mature on December 12, 2030 and accrue interest at a rate of 4.750% per annum, payable semi-annually on June 12 and December 12 of each year, beginning on June 12, 2026. We may redeem for cash all or any portion of the notes, at our option, at any time prior to maturity at make-whole premium redemption prices defined in the form of the notes. 4.650% Term Notes due 2026 (2026 Term Notes) In September 2024, we issued $500 million aggregate principal amount of 2026 Term Notes, which mature on September 9, 2026 and accrue interest at a rate of 4.650% per annum, payable semi-annually on Ma …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Our revenue is generated from the sale of products and services. Product revenue consists of sales of instruments and consumables used in genetic analysis. Service and other revenue consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Revenue by Source Q2 2026 Q2 2025 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 775 $ 77 $ 852 $ 740 $ 71 $ 811 Instruments 125 5 130 96 5 101 Total product revenue 900 82 982 836 76 912 Service and other revenue 154 23 177 136 11 147 Total revenue $ 1,054 $ 105 $ 1,159 $ 972 $ 87 $ 1,059 YTD 2026 YTD 2025 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 1,500 $ 149 $ 1,649 $ 1,437 $ 143 $ 1,580 Instruments 243 7 250 204 9 213 Total product revenue 1,743 156 1,899 1,641 152 1,793 Service and other revenue 306 46 352 277 30 307 Total revenue $ 2,049 $ 202 $ 2,251 $ 1,918 $ 182 $ 2,100 Revenue by Geographic Area Based on region of destination (in millions) Q2 2026 Q2 2025 (1) YTD 2026 YTD 2025 (1) United States and Canada $ 653 $ 569 $ 1,243 $ 1,125 Europe, Middle East, Africa and Latin America 368 355 725 686 Greater China (2) 56 63 108 135 Asia-Pacific 82 72 175 154 Total revenue $ 1,159 $ 1,059 $ 2,251 $ 2,100 _____________ (1) We implemented a new global commercial structure in Q1 2026 to improve operating efficiencies and better align with local markets. Beginning in Q1 2026, we began r …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

4. INVESTMENTS AND FAIR VALUE MEASUREMENTS Strategic Investments Marketable Equity Securities Our marketable equity securities consist primarily of our retained investment in GRAIL subsequent to our divestiture in 2024. As of June 28, 2026 and December 28, 2025, the fair value of our marketable equity securities, included in short-term investments, totaled $88 million and $215 million, respectively. Gains (losses) recognized in other income (expense), net on marketable equity securities were as follows: In millions Q2 2026 Q2 2025 YTD 2026 YTD 2025 Net gains (losses) recognized during the period $ 22 $ 97 $ (23) $ 128 Less: Net gains recognized during the period on securities sold during the period 12 Net unrealized gains (losses) recognized during the period on securities still held at the reporting date $ 22 $ 97 $ (35) $ 128 Non-Marketable Equity Securities As of June 28, 2026 and December 28, 2025, non-marketable equity securities, without readily determinable fair values, included in other assets, were $59 million and $58 million, respectively. Venture Funds We invest in three venture capital investment funds (the Funds), which are accounted for as equity-method investments. The aggregate carrying amount of the Funds, included in other assets, was $273 million and $235 million as of June 28, 2026 and December 28, 2025, respectively, with associated gains and losses recognized in other income (expense), net. We recognized net gains of $7 million and $14 million in Q2 2026 …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

9. INCOME TAXES Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income (loss) before income taxes and taxable income. Our effective tax rates for Q2 2026 and YTD 2026 were 20.5% and 18.4%, respectively, compared to 23.4% and 25.1% in Q2 2025 and YTD 2025, respectively. The variance from the U.S. federal statutory tax rate of 21% in YTD 2026 was primarily due to prior year tax return adjustments. The tax rate in Q2 2026 and YTD 2026 was favorably impacted by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore. As of both June 28, 2026 and December 28, 2025, prepaid income taxes, included within prepaid expenses and other current assets on the condensed consolidated balance sheets, were $81 million.

IncomeTaxDisclosureTextBlock

8. LEGAL PROCEEDINGS We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the condensed consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. Shareholder Derivative Complaints On October 17, 2023, a stockholder derivative and class action complaint captioned Icahn Partners LP, et al. v. deSouza, et al. , purportedly brought on behalf of Illumina and public holders of Illumi …

LegalMattersAndContingenciesTextBlock · excerpt; the full note is in the filing

Accounting Pronouncements Pending Adoption In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. The new standard requires a company to provide disaggregated disclosures, in the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard is effective for us beginning in fiscal year 2027 and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software . The new standard is intended to modernize the recognition and disclosure framework for capitalized internal-use software costs, removing the previous development stage model and introducing a more judgment-based approach. The standard is effective for us beginning in our first quarter of fiscal year 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements. In November 2025, the FASB issued ASU 2025-09, Derivativ …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

3. REVENUE Our revenue is generated from the sale of products and services. Product revenue consists of sales of instruments and consumables used in genetic analysis. Service and other revenue consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Revenue by Source Q2 2026 Q2 2025 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 775 $ 77 $ 852 $ 740 $ 71 $ 811 Instruments 125 5 130 96 5 101 Total product revenue 900 82 982 836 76 912 Service and other revenue 154 23 177 136 11 147 Total revenue $ 1,054 $ 105 $ 1,159 $ 972 $ 87 $ 1,059 YTD 2026 YTD 2025 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 1,500 $ 149 $ 1,649 $ 1,437 $ 143 $ 1,580 Instruments 243 7 250 204 9 213 Total product revenue 1,743 156 1,899 1,641 152 1,793 Service and other revenue 306 46 352 277 30 307 Total revenue $ 2,049 $ 202 $ 2,251 $ 1,918 $ 182 $ 2,100 Revenue by Geographic Area Based on region of destination (in millions) Q2 2026 Q2 2025 (1) YTD 2026 YTD 2025 (1) United States and Canada $ 653 $ 569 $ 1,243 $ 1,125 Europe, Middle East, Africa and Latin America 368 355 725 686 Greater China (2) 56 63 108 135 Asia-Pacific 82 72 175 154 Total revenue $ 1,159 $ 1,059 $ 2,251 $ 2,100 _____________ (1) We implemented a new global commercial structure in Q1 2026 to improve operating efficiencies and better align with local markets. Beginning in Q1 2026, …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

10. SEGMENT INFORMATION As of June 28, 2026, we have one reportable segment. Segment information is consistent with how our Chief Operating Decision Maker (CODM), who is our Chief Executive Officer, reviews financial information, makes operating decisions, allocates resources, and assesses performance. We also consider the way budgets and forecasts are prepared and reviewed and the basis on which executive compensation is determined. Our CODM allocates resources and evaluates business performance based on consolidated revenue and net income. Net income is used in the annual budgeting and monthly forecasting processes and to monitor and assess budgeted/forecasted versus actual results. Our CODM does not evaluate segments using asset information. The following table presents selected financial information with respect to segment profit for the periods presented: In millions Q2 2026 Q2 2025 YTD 2026 YTD 2025 Revenue $ 1,159 $ 1,059 $ 2,251 $ 2,100 Less: Cost of revenue 389 364 760 722 Research and development 252 247 492 499 Selling and marketing 164 146 322 311 General and administrative 109 88 223 190 Income from operations 245 214 454 378 Other income (expense), net 15 92 (37) 110 Provision for income taxes 53 71 77 122 Net income $ 207 $ 235 $ 340 $ 366

SegmentReportingDisclosureTextBlock